Search results for: Market Access
Filter search results
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
…antibiotics lose effectiveness over time as bacteria become resistant to them, but the market for new antibiotics is not commercially viable for reasons that are well documented, resulting in a…
OHE Seminar: Patents, Price Controls, and the Global Diffusion of New Drugs
5 June 2016, 11:00pm
…Productivity Crisis” in Innovation Policy and the Economy, “The Market for Follow-on Biologics: How Will It Evolve?” in Health Affairs, “The Hidden Cost of Low Prices: Access to New Drugs…
Our Contributions to the Economics of Personalised Medicine
7 March 2018
…pricing and market access agreements This strand of research considers various pricing strategies to incentivise the R&D of personalised medicines and increase their uptake. This includes incentivising combination therapies…
OHE at ISPOR Europe 2018
…devices or procedures. Authors of these papers, including Adrian Towse, will present on topics that include regulatory and market access challenges, methodological issues in assessing the value of such interventions,…
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
…R., 2017. 2. How is the economic assessment of vaccines performed today? Journal of Market Access & Health Policy, 5(1), p.1335163. 10.1080/20016689.2017.1335163. Thindwa, D., Garcia Quesada, M., Liu, Y., Bennett,…
The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’
3 December 2020
…Heart Failure Policy Network, followed by presentations from Ms Sophie Marie Meiser, Manager of Market Access and Economic Policies at MedTech Europe, and Bernarda Zamora, Senior Economist at the Office…
Personalised Medicine and the Value of Molecular Diagnostics: Case Studies
18 December 2013
…open-access publication, OHE’s Adrian Towse and his co-authors examine nine case studies of diagnostics that have been successful in advancing personalised medicine. Progress in personalised medicine is slower than some…
OHE at ISPOR Latin America: Policy Options for Formulary Development in Middle-income Countries
20 October 2015
…in definition of health benefit plans. ISPOR 5th Latin America Conference, Increasing Access to Health Care in Latin America: Making Better Decisions for Greater Equity, took place on 6-8 September…
Reforming Primary Health Care in Middle-Income Countries: The Good, the Bad, and the Ugly
18 July 2022
…delivery care services; women’s access to health care; and child health status in Egypt. The authors show that the imposition of user fees did not negatively affect the utilisation of…